Fusen Pharmaceutical Co (HKSE:01652) Debt-to-Equity : 0.61 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Fusen Pharmaceutical Co Debt-to-Equity?

Fusen Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$259.9 Mil. Fusen Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$116.5 Mil. Fusen Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$616.4 Mil. Fusen Pharmaceutical Co's debt to equity for the quarter that ended in Dec. 2023 was 0.61.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Fusen Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

HKSE:01652' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.3 Med: 0.37 Max: 4.96
Current: 0.61

During the past 9 years, the highest Debt-to-Equity Ratio of Fusen Pharmaceutical Co was 4.96. The lowest was 0.30. And the median was 0.37.

HKSE:01652's Debt-to-Equity is ranked worse than
71.23% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs HKSE:01652: 0.61

Fusen Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Fusen Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusen Pharmaceutical Co Debt-to-Equity Chart

Fusen Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.31

0.30

0.37

0.61

Fusen Pharmaceutical Co Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial											0.37	0.44	0.37	0.47	0.61

Competitive Comparison of Fusen Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Fusen Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusen Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fusen Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Fusen Pharmaceutical Co's Debt-to-Equity falls into.

Fusen Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Fusen Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(259.929	+	116.457)	/	616.364
	=	0.61

Fusen Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(259.929	+	116.457)	/	616.364
	=	0.61

Fusen Pharmaceutical Co (HKSE:01652) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Fusen Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Fusen Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusen Pharmaceutical Co (HKSE:01652) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fusen Pharmaceutical Co Ltd (HKSE:01652) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Urban Industrial Zone, Henan Province, Xichuan County, Zhengzhou, CHN

Website

http://www.fusenyy.com

Fusen Pharmaceutical Co Ltd is engaged in manufacturing shuanghuanglian based cold medicine. The product portfolio company includes shuanghuanglian based cold medicine and which includes oral solutions and shuanghuanglian injections, other PCM and western medicine products which include compound ferrous sulphate granules and flunarizine hydrochloride capsules.

Executives

Cao Changcheng	2201 Interest of corporation controlled by you
Quan Xiufeng	2202 Interest of your spouse
Full Bliss Holdings Limited	2101 Beneficial owner
One Victory Investments Limited	2101 Beneficial owner
Cao Zhiming	2201 Interest of corporation controlled by you
Zhou Peilin	2202 Interest of your spouse
Rayford Global Limited	2306 Nominee for another person
Tct (bvi) Limited	2501 Other
The Core Trust Company Limited	2301 Trustee
First Joint Elegant Limited	2101 Beneficial owner
Fung Wai Sze	2202 Interest of your spouse
Lam Yiu Por	2201 Interest of corporation controlled by you

Fusen Pharmaceutical Co (HKSE:01652) Headlines

No Headlines